FLT3 Length Mutations as Marker for Follow-Up Studies in Acute Myeloid Leukaemia

Publisher： Karger

E-ISSN： 1421-9662|112|1-2|68-78

ISSN： 0001-5792

Source： Acta Haematologica, Vol.112, Iss.1-2, 2004-06, pp. : 68-78

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 5, 2015-06 ,pp. : 694-700

John Wiley & Sons Inc

Access to resources Recommend Favorite

Implications of FLT3 Mutations in the Therapy of Acute Myeloid Leukemia

By  

Reviews on Recent Clinical Trials, Vol. 2, Iss. 2, 2007-05 ,pp. : 135-141

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment with FLT3 inhibitor in patients with FLT3‐mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations

By  

CANCER, Vol. 120, Iss. 14, 2014-07 ,pp. : 2142-2149

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Implications of Non-A-Type NPM1 and FLT3 Mutations in Patients with Normal Karyotype Acute Myeloid Leukemia

By  

Acta Haematologica, Vol. 127, Iss. 2, 2011-11 ,pp. : 63-71

Karger

Access to resources Recommend Favorite

Sorafenib Treatment in 13 Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations in Combination with Chemotherapy or as Monotherapy

By  

Acta Haematologica, Vol. 124, Iss. 3, 2010-10 ,pp. : 153-159

Karger

Access to resources Recommend Favorite